Related Experiment Videos
18F-FDG PET in children with lymphomas
Gisele Depas1, Caroline De Barsy, Guy Jerusalem
1Division of Nuclear Medicine, University Hospital, Liège, Belgium. gisele.depas@chu.ulg.ac.be
European Journal of Nuclear Medicine and Molecular Imaging
|December 18, 2004
Summary
18F-FDG-PET imaging is valuable for assessing pediatric lymphomas. While effective, further prospective studies are needed to confirm its full impact on patient management and treatment strategies.
Area of Science:
- Nuclear medicine
- Pediatric oncology
Background:
- Lymphomas are a significant concern in pediatric oncology.
- Accurate staging and treatment response assessment are crucial for effective management.
Purpose of the Study:
- To retrospectively evaluate the performance of 18F-fluorodeoxyglucose-positron emission tomography (18F-FDG-PET) in children with lymphomas.
- To assess PET's utility across various disease stages and treatment points.
Main Methods:
- Retrospective analysis of 113 whole-body PET scans in 28 children (median age 12.5 years) with Hodgkin's disease or non-Hodgkin's lymphoma.
- Comparison of PET findings with conventional methods (CMs) at initial staging, during treatment, end of treatment, and follow-up.
Main Results:
- PET influenced staging and treatment decisions in 10.5% of initial evaluations.
- PET demonstrated high specificity (94-95%) in evaluating treatment end and follow-up, outperforming CMs (54-66%).
- PET showed a low false-positive rate, though it missed some relapses in early treatment response assessment.
Conclusions:
- 18F-FDG-PET is a beneficial imaging modality for pediatric lymphomas.
- Prospective research is essential to fully establish PET's role in optimizing patient care and management strategies.